IceCure Medical Ltd. Announces Positive Clinical Data for ProSense® Cryoablation Technology

IceCure Medical Ltd. presented data at the European Conference on Interventional Oncology (ECIO) 2026 highlighting the efficacy of its ProSense® cryoablation system. The ICESECRET trial showed an 89.4% recurrence-free rate for kidney cancer in patients with tumors ≤3 cm, with a median follow-up of 4.0 years. An independent study on early-stage breast cancer reported no residual cancer at 6 and 12 months post-procedure, with 100% of patients achieving excellent cosmetic outcomes. Additionally, a study on breast fibroadenomas demonstrated a 92.9% volume reduction at 12 months post-treatment with ProSense®. The company also noted significant interest and participation in a dedicated breast cryoablation master class at ECIO 2026, underscoring the growing clinical validation and versatility of their cryoablation technology for various oncological indications.